Transcode Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Transcode Therapeutics
RNAZ Stock  USD 0.34  0.04  9.71%   
Transcode Therapeutics financial statements provide useful quarterly and yearly information to potential Transcode Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Transcode Therapeutics financial statements helps investors assess Transcode Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Transcode Therapeutics' valuation are summarized below:
Market Capitalization
6.5 M
Earnings Share
168.84
We have found one hundred thirteen available fundamental trend indicators for Transcode Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Transcode Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 48.1 K, Tax Provision of 0.0 or Net Interest Income of 15.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Transcode Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities2 M3.5 M927.2 K
Slightly volatile
Other Liabilities2.4 M2.3 M824.8 K
Slightly volatile
Total Current Assets6.6 M4.5 M2.9 M
Slightly volatile
Common Stock59.8563.0701
Pretty Stable
Total Assets8.1 M5.2 M3.1 M
Slightly volatile
Short and Long Term Debt Total385.2 K405.5 K870.4 K
Slightly volatile
Other Current Liabilities3.7 M3.5 M900.7 K
Slightly volatile
Accounts Payable2 M2.3 M755.8 K
Slightly volatile
Cash2.6 M2.8 M2.3 M
Slightly volatile
Non Current Assets Total750 K714.3 K148.4 K
Slightly volatile
Long Term Debt1.7 M2.4 M1.3 M
Slightly volatile
Cash And Short Term Investments2.6 M2.8 M2.3 M
Slightly volatile
Common Stock Total Equity371418455
Slightly volatile
Common Stock Shares Outstanding188 K179 K31.4 K
Slightly volatile
Liabilities And Stockholders Equity8.1 M5.2 M3.1 M
Slightly volatile
Non Current Liabilities Total36.4 K38.3 K1.4 M
Very volatile
Total Liabilities3.6 M3.5 M2.1 M
Slightly volatile
Capital Stock59.8563.0521
Very volatile
Net Working Capital916.6 K964.8 K1.8 M
Slightly volatile
Short Term Investments8.0710.824.8607
Slightly volatile
Other Current Assets1.5 M1.7 M475.5 K
Slightly volatile
Deferred Long Term Liabilities179.3 K201.7 K219.7 K
Slightly volatile
Current Deferred Revenue23 K24.4 K29.4 K
Slightly volatile
Property Plant And Equipment Gross536 K865.7 K314.7 K
Slightly volatile
Short Term Debt352.5 K371.1 K1.7 M
Slightly volatile
Property Plant Equipment165 K185.6 K202.1 K
Slightly volatile
Net Receivables288.2 K324.2 K353 K
Slightly volatile
Inventory443.5 K498.9 K543.2 K
Slightly volatile

Transcode Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income7.9 K14.8 K3 K
Slightly volatile
Depreciation And Amortization304.6 K516.7 K112.6 K
Slightly volatile
Selling General Administrative7.5 B7.2 B978.8 M
Slightly volatile
Other Operating Expenses20.4 M19.4 M4.6 M
Slightly volatile
Research Development12.9 M12.3 M2.7 M
Slightly volatile
Total Operating Expenses20.4 M19.4 M4.6 M
Slightly volatile
Income Tax Expense3.84.01.3 M
Slightly volatile
Cost Of Revenue542.6 K516.7 K111.2 K
Slightly volatile

Transcode Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings820.3 K1.4 M745.5 K
Slightly volatile
Depreciation542.6 K516.7 K111.2 K
Slightly volatile
Capital Expenditures33.8 K35.6 K215.2 K
Slightly volatile
Total Cash From Financing Activities8 M15.9 M3.7 M
Slightly volatile
End Period Cash Flow5.5 M2.8 M2.5 M
Slightly volatile
Change To Netincome764.7 K1.2 M426.6 K
Slightly volatile
Stock Based Compensation1.1 M1 M184.4 K
Slightly volatile
Begin Period Cash Flow5.9 M5 M2.3 M
Slightly volatile
Change To Inventory288.2 K324.2 K353 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.7 M2.9 M1.3 M
Slightly volatile
Capex To Depreciation0.06550.06890.896
Slightly volatile
Inventory Turnover0.140.160.1742
Slightly volatile
Days Of Inventory On Hand1.6 K1.8 K2 K
Slightly volatile
Payables Turnover0.01750.02040.0209
Slightly volatile
Cash Per Share14.6915.4614184
Slightly volatile
Days Payables Outstanding18.4 K18.5 K17.4 K
Pretty Stable
Income Quality0.580.97460.681
Pretty Stable
Current Ratio1.211.27642.3248
Pretty Stable
Graham Number139146966
Slightly volatile
Capex Per Share0.190.198919.8023
Slightly volatile
Average Receivables144.1 K162.1 K176.5 K
Slightly volatile
Interest Debt Per Share0.270.2828150
Pretty Stable
Debt To Assets3.192.272.381
Pretty Stable
Days Of Payables Outstanding18.4 K18.5 K17.4 K
Pretty Stable
Ebt Per Ebit1.610.95511.3201
Pretty Stable
Quick Ratio1.211.27642.3163
Pretty Stable
Net Income Per E B T1.261.171.214
Slightly volatile
Cash Ratio0.750.79292.1657
Pretty Stable
Days Of Inventory Outstanding1.6 K1.8 K2 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.0021.0473
Very volatile
Debt Ratio3.192.272.381
Pretty Stable

Transcode Fundamental Market Drivers

Cash And Short Term Investments2.8 M

Transcode Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue24.4 K23 K
Cost Of Revenue516.7 K542.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY